Sergey O. Mazurenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sergey O. Mazurenko has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- N. Yu. Semigolovskii
St Petersburg State University
10 shared publications - Larisa G. Ermolaeva
Saint Petersburg State University
5 shared publications - Ivan Yu. Pchelin
Saint Petersburg State University
4 shared publications - Natalia Khudyakova
St Petersburg State University
4 shared publications - S. N. Semigolovskii
Scientific Research Medical Center “Deoma
4 shared publications - Viktor V. Smirnov
Санкт-Петербургский государственный педиатрический медицинский университет
4 shared publications
Latest Publications
- Open Access
- 25 June 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 7,p. 280-287
Atrial fibrillation in sepsis and the potential effects of propafenone and levocarnitine
Actually sepsis is one of the most important health problems, as the incidence of it in the world is high and continues to grow, and mortality reaches 40–60%, especially with the development of septic shock. Frequent heart damage in sepsis – septic cardiomyopathy (an established term for sepsis-caused by acute cardiac dysfunction syndrome unrelated to ischemia due to damage to the coronary arteries) – is often complicated by the occurrence of cardiac arrhythmias. Ventricular arrhythmias are rare, and atrial fibrillation develops in 20–30% of cases, reaching 45% with septic shock. At the same time, mortality increases by about 2–3 times if attempts at cardioversion are unsuccessful. However, the issues of antiarrhythmic therapy have not yet been regulated. The Russian and Eurasian clinical guidelines for the treatment of atrial fibrillation (2025) do not mention sepsis. And the recommendations of the European Society of Cardiology and the Association of Cardiothoracic Surgeons (2024), supplemented by the European Heart Rhythm Association (2025), only state that sepsis is a trigger for atrial fibrillation and a risk factor for its subsequent recurrence in almost half of the discharged patients with sepsis, and the degree of inflammation correlates with the frequency of its development and recurrence. Drugs commonly used for cardioversion – beta-blockers, calcium antagonists, amiodarone – can worsen the situation, negatively affecting the hemodynamics of septic patients, especially in shock. The culprits of the hipotensive effect of amiodarone, in particular, are due of the emulsifier polysorbate-80 and benzyl alcohol in its composition. Based on an analysis of current clinical studies and our own clinical experience, the article examines the use of propafenone in this case, devoid of cardiodepressive properties. It is also advisable to use levocarnitine adjuvantly, which has positive inotropic and antioxidant properties, as well as being able to resist inflammatory and proarrhythmic links in the pathogenesis of sepsis, and prevent recurrence.
- 25 June 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 7,p. 280-287
Open AccessAtrial fibrillation in sepsis and the potential effects of propafenone and levocarnitine
Actually sepsis is one of the most important health problems, as the incidence of it in the world is high and continues to grow, and mortality reaches 40–60%, especially with the development of septic shock. Frequent heart damage in sepsis – septic cardiomyopathy (an established term for sepsis-caused by acute cardiac dysfunction syndrome unrelated to ischemia due to damage to the coronary arteries) – is often complicated by the occurrence of cardiac arrhythmias. Ventricular arrhythmias are rare, and atrial fibrillation develops in 20–30% of cases, reaching 45% with septic shock. At the same time, mortality increases by about 2–3 times if attempts at cardioversion are unsuccessful. However, the issues of antiarrhythmic therapy have not yet been regulated. The Russian and Eurasian clinical guidelines for the treatment of atrial fibrillation (2025) do not mention sepsis. And the recommendations of the European Society of Cardiology and the Association of Cardiothoracic Surgeons (2024), supplemented by the European Heart Rhythm Association (2025), only state that sepsis is a trigger for atrial fibrillation and a risk factor for its subsequent recurrence in almost half of the discharged patients with sepsis, and the degree of inflammation correlates with the frequency of its development and recurrence. Drugs commonly used for cardioversion – beta-blockers, calcium antagonists, amiodarone – can worsen the situation, negatively affecting the hemodynamics of septic patients, especially in shock. The culprits of the hipotensive effect of amiodarone, in particular, are due of the emulsifier polysorbate-80 and benzyl alcohol in its composition. Based on an analysis of current clinical studies and our own clinical experience, the article examines the use of propafenone in this case, devoid of cardiodepressive properties. It is also advisable to use levocarnitine adjuvantly, which has positive inotropic and antioxidant properties, as well as being able to resist inflammatory and proarrhythmic links in the pathogenesis of sepsis, and prevent recurrence.
- 26 January 2026
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 29 (4)
The effect of a low-carbohydrate diet on renal dysfunction in patients with metabolic disorders. Description of clinical cases
Currently, the leading factors in the development and progression of chronic kidney disease (CKD) are type 2 diabetes mellitus and arterial hypertension, which are often caused by obesity resulting from overeating. The literature clearly shows that a properly selected diet has a beneficial effect not only on blood pressure and carbohydrate metabolism, but also on kidney function. The presence of CKD in most cases assumes comorbidity, and therefore requires the selection of an optimal diet that includes correction of all existing metabolic disorders. Today, there are more than 100 diets known, but it remains unclear which one is best for these patients. Moreover, the effect of major macronutrients on renal function remains controversial and has not been fully studied. The article describes three clinical cases of a low-carbohydrate diet (LCD) with moderate carbohydrate intake and its effect on renal function and metabolic parameters. This dietary option in patients with metabolic disorders, combined with high patient adherence to the diet, led to improved kidney function and carbohydrate, lipid and purine metabolism indicators, weight loss, a reduction in the doses and number of medications used, and in some cases helped to normalise blood pressure.
- 26 January 2026
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 29 (4)
The effect of a low-carbohydrate diet on renal dysfunction in patients with metabolic disorders. Description of clinical cases
Currently, the leading factors in the development and progression of chronic kidney disease (CKD) are type 2 diabetes mellitus and arterial hypertension, which are often caused by obesity resulting from overeating. The literature clearly shows that a properly selected diet has a beneficial effect not only on blood pressure and carbohydrate metabolism, but also on kidney function. The presence of CKD in most cases assumes comorbidity, and therefore requires the selection of an optimal diet that includes correction of all existing metabolic disorders. Today, there are more than 100 diets known, but it remains unclear which one is best for these patients. Moreover, the effect of major macronutrients on renal function remains controversial and has not been fully studied. The article describes three clinical cases of a low-carbohydrate diet (LCD) with moderate carbohydrate intake and its effect on renal function and metabolic parameters. This dietary option in patients with metabolic disorders, combined with high patient adherence to the diet, led to improved kidney function and carbohydrate, lipid and purine metabolism indicators, weight loss, a reduction in the doses and number of medications used, and in some cases helped to normalise blood pressure.
- 20 November 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 251-258
Low-carbohydrate diets in diabetes mellitus: A clinical case report and a brief literature review
Despite the numerous groups of hypoglycaemic drugs available, disability and mortality from complications of diabetes mellitus (DM) are increasing every year. This requires new effective approaches to the management of patients with DM. One of these approaches is diet therapy. Diet is considered the most important component of DM treatment by all authoritative organisations. Before the discovery of insulin, carbohydrate-restricted diets were widely used for DМ, but recently, leading publications have reported that dietary correction with carbohydrate restriction is required without clear guidelines on the extent of such restriction, and the focus is mainly on drug treatment. Analysis of the literature confirms the positive effect of low-carbohydrate diets (LCD) on weight loss, improvement of the glycaemic profile in DМ, and reducing the number and doses of hypoglycaemic drugs, but it remains unclear which diet to choose in a certain situation, which one will give the best results and be safe in the short and long term. Studies on this issue have been conducted, but their results are contradictory. To date, there is no consensus on which LCD diet is the optimal solution for DМ. The article describes a clinical case of four months treatment of LCD with moderate carbohydrate intake and its effect on weight, metabolic parameters, and hypoglycaemic therapy in a patient with long-term DM, corrected with insulin therapy for the last 10 years. This diet, combined with the patient’s high compliance, led to an 11-kilogram weight loss, improved carbohydrate metabolism and withdrawal from insulin therapy, as well as helped normalise blood pressure without the treatment of antihypertensive drugs and improved kidney function.
- 20 November 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 251-258
Low-carbohydrate diets in diabetes mellitus: A clinical case report and a brief literature review
Despite the numerous groups of hypoglycaemic drugs available, disability and mortality from complications of diabetes mellitus (DM) are increasing every year. This requires new effective approaches to the management of patients with DM. One of these approaches is diet therapy. Diet is considered the most important component of DM treatment by all authoritative organisations. Before the discovery of insulin, carbohydrate-restricted diets were widely used for DМ, but recently, leading publications have reported that dietary correction with carbohydrate restriction is required without clear guidelines on the extent of such restriction, and the focus is mainly on drug treatment. Analysis of the literature confirms the positive effect of low-carbohydrate diets (LCD) on weight loss, improvement of the glycaemic profile in DМ, and reducing the number and doses of hypoglycaemic drugs, but it remains unclear which diet to choose in a certain situation, which one will give the best results and be safe in the short and long term. Studies on this issue have been conducted, but their results are contradictory. To date, there is no consensus on which LCD diet is the optimal solution for DМ. The article describes a clinical case of four months treatment of LCD with moderate carbohydrate intake and its effect on weight, metabolic parameters, and hypoglycaemic therapy in a patient with long-term DM, corrected with insulin therapy for the last 10 years. This diet, combined with the patient’s high compliance, led to an 11-kilogram weight loss, improved carbohydrate metabolism and withdrawal from insulin therapy, as well as helped normalise blood pressure without the treatment of antihypertensive drugs and improved kidney function.
- 20 November 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 61-68
Cardioprotection method for percutaneous coronary interventions in elderly patients with acute coronary syndrome
Introduction . Acute coronary syndrome (ACS) is the main cause of death in elderly patients who suffer worse from percutaneous coronary interventions (PCI), and new cardioprotection techniques are in high demand. Aim . To study the efficacy of levocarnitine in preventing complications due to PCI in elderly patients with acute coronary syndrome. Materials and methods . 80 ACS patients were randomized into 2 groups of 40 people: the main group was the average age of 78 (75, 93), received 1.0 g of levocarnitine intracoronary, followed by an intravenous infusion of 2.0 g/day for 3 days; and the control group of age 77 (75, 91) received placebo administration. PCI was performed an average of 3.5 hours after the onset of ACS symptoms. The MB fraction of creatine phosphokinase (CPK-MV) and highly sensitive troponin I (hsTrI), ECG and EchoCG parameters in dynamics, course and outcomes were determined. Results . The dynamics of biomarker levels was more favorable in the main group, where there was a smaller increase in hsTrI at 1 day after PCI and an accelerated decrease at 3 day after PCI. CPK-MB on day 3 in the main group was significantly lower than the control level (p < 0.001). The significantly lower average left ventricular ejection fraction in the main group initially (p < 0.023) significantly exceeded the control level on day 3 after PCI (p < 0.001). There was a faster positive dynamics of the ECG and a tendency to decrease the frequency of arrhythmic episodes in the main group compared with the control group. There was no hospital mortality in the main group, and it was 10.0% in the control group. Conclusions . The described technique of adjuvant cardioprotection in PCI appears to be an available, effective and safe addition to the standard provision of reperfusion in elderly patients with ACS.
- 20 November 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 61-68
Cardioprotection method for percutaneous coronary interventions in elderly patients with acute coronary syndrome
Introduction . Acute coronary syndrome (ACS) is the main cause of death in elderly patients who suffer worse from percutaneous coronary interventions (PCI), and new cardioprotection techniques are in high demand. Aim . To study the efficacy of levocarnitine in preventing complications due to PCI in elderly patients with acute coronary syndrome. Materials and methods . 80 ACS patients were randomized into 2 groups of 40 people: the main group was the average age of 78 (75, 93), received 1.0 g of levocarnitine intracoronary, followed by an intravenous infusion of 2.0 g/day for 3 days; and the control group of age 77 (75, 91) received placebo administration. PCI was performed an average of 3.5 hours after the onset of ACS symptoms. The MB fraction of creatine phosphokinase (CPK-MV) and highly sensitive troponin I (hsTrI), ECG and EchoCG parameters in dynamics, course and outcomes were determined. Results . The dynamics of biomarker levels was more favorable in the main group, where there was a smaller increase in hsTrI at 1 day after PCI and an accelerated decrease at 3 day after PCI. CPK-MB on day 3 in the main group was significantly lower than the control level (p < 0.001). The significantly lower average left ventricular ejection fraction in the main group initially (p < 0.023) significantly exceeded the control level on day 3 after PCI (p < 0.001). There was a faster positive dynamics of the ECG and a tendency to decrease the frequency of arrhythmic episodes in the main group compared with the control group. There was no hospital mortality in the main group, and it was 10.0% in the control group. Conclusions . The described technique of adjuvant cardioprotection in PCI appears to be an available, effective and safe addition to the standard provision of reperfusion in elderly patients with ACS.
- 3 September 2025
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 29 (3) , 8-30
Therapeutic nutrition of elderly people with kidney diseases
Kidney diseases belong to a common category of pathology in the elderly and senile age, in which diet therapy occupies one of the central places in complex treatment. Assessment of metabolic disorders in the body of older people with diseases of the urinary system is the most important condition for diet therapy. It should be based on an integrated approach, including anthropometric data on the patient, biochemical information on the state of water-electrolyte, protein-energy, fat, carbohydrate, vitamin-mineral metabolism. The task of implementing nutritional support for the elderly with various nephrological pathologies includes a nosologically appropriate and personalized definition of dietary strategy in choosing patient nutrition, dietary rhythms, dietary programs and diets. The lecture presents methods recommended in Russian and international consensus for the quantitative formulation of diets that take into account the nature and severity of metabolic disorders and pathogenetic features of existing kidney pathology and the severity of involution processes in the body of the elderly and elderly. Algorithms for choosing individually justified diets for various kidney diseases, their severity, and the formation of complications are presented, taking into account the implementation of various therapy programs, including pharmacotherapy options and reasonable types of dialysis. The possibilities of the influence of certain foods and their combinations on reducing the intensity of the mechanisms of development and progression of renal pathology are described. Gerontodietology in clinical nephrology should be considered as the most important component of a comprehensive treatment program, the individualization of which should be based on a thorough study of the patient's metabolic features, understanding the pathogenetic features of the occurrence and chronization of kidney pathology, understanding the essence of involutional processes in the supervised patient and using the extensive knowledge of a creative and erudite doctor to block these identified somatic features. an individualized diet.
- 3 September 2025
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 29 (3) , 8-30
Therapeutic nutrition of elderly people with kidney diseases
Kidney diseases belong to a common category of pathology in the elderly and senile age, in which diet therapy occupies one of the central places in complex treatment. Assessment of metabolic disorders in the body of older people with diseases of the urinary system is the most important condition for diet therapy. It should be based on an integrated approach, including anthropometric data on the patient, biochemical information on the state of water-electrolyte, protein-energy, fat, carbohydrate, vitamin-mineral metabolism. The task of implementing nutritional support for the elderly with various nephrological pathologies includes a nosologically appropriate and personalized definition of dietary strategy in choosing patient nutrition, dietary rhythms, dietary programs and diets. The lecture presents methods recommended in Russian and international consensus for the quantitative formulation of diets that take into account the nature and severity of metabolic disorders and pathogenetic features of existing kidney pathology and the severity of involution processes in the body of the elderly and elderly. Algorithms for choosing individually justified diets for various kidney diseases, their severity, and the formation of complications are presented, taking into account the implementation of various therapy programs, including pharmacotherapy options and reasonable types of dialysis. The possibilities of the influence of certain foods and their combinations on reducing the intensity of the mechanisms of development and progression of renal pathology are described. Gerontodietology in clinical nephrology should be considered as the most important component of a comprehensive treatment program, the individualization of which should be based on a thorough study of the patient's metabolic features, understanding the pathogenetic features of the occurrence and chronization of kidney pathology, understanding the essence of involutional processes in the supervised patient and using the extensive knowledge of a creative and erudite doctor to block these identified somatic features. an individualized diet.
- Open Access
- 20 May 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 6,p. 234-239
X-linked adrenoleukodystrophy: a case report
In this article, we described а clinical case of a 32-year-old patient with late diagnosis of adrenomyeloneuropathy manifested with gradually increasing neurologic symptoms, mistakenly considered as hereditary spastic paraparesis, later joined by adrenal insufficiency. It is known that ALD is characterized by a pronounced phenotypic polymorphism, which is associated with differences in penetrance and expression of the abnormal gene. The patient was examined for pathogenic mutations associated with spastic paraplegia and hereditary diseases with similar phenotypic manifestations (Neurodegenerative Diseases panel including analysis of 723 genes). No significant changes meeting the search criteria were found. However, the absence of point mutations associated with ALD does not exclude this diagnosis, but requires the exclusion of chromosomal rearrangements by sequencing the ABCD1 gene. This study was not performed on the patient, which subsequently led to the misdiagnosis. Despite the fact that current clinical guidelines allow the diagnosis of ALD without genetic confirmation, due to the variety of ALD “masks” and frequent untimely diagnosis of this disease, sequencing of the ABCD1 gene is advisable. In order to correct adrenal insufficiency, the patient was prescribed hormone replacement therapy (HRT) with hydrocortisone, which eliminated the main clinical manifestations and partially laboratory signs of hypocorticism. However, corticotropin levels indicated inadequacy of HRT and increased risk of secondary corticotropinoma growth. However, the patient has been receiving intrathecal therapy with the GABA agonist baclofen for the past five years. The literature has not yet described the response of stress hormones to intrathecal administration of baclofen in patients with primary hypocorticism. The few data available indicate that GABA agonists may have a multidirectional effect on hypothalamic-pituitary function; therefore, it is difficult to determine the contribution of this effect on corticotropin secretion in this patient.
- 20 May 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 6,p. 234-239
Open AccessX-linked adrenoleukodystrophy: a case report
In this article, we described а clinical case of a 32-year-old patient with late diagnosis of adrenomyeloneuropathy manifested with gradually increasing neurologic symptoms, mistakenly considered as hereditary spastic paraparesis, later joined by adrenal insufficiency. It is known that ALD is characterized by a pronounced phenotypic polymorphism, which is associated with differences in penetrance and expression of the abnormal gene. The patient was examined for pathogenic mutations associated with spastic paraplegia and hereditary diseases with similar phenotypic manifestations (Neurodegenerative Diseases panel including analysis of 723 genes). No significant changes meeting the search criteria were found. However, the absence of point mutations associated with ALD does not exclude this diagnosis, but requires the exclusion of chromosomal rearrangements by sequencing the ABCD1 gene. This study was not performed on the patient, which subsequently led to the misdiagnosis. Despite the fact that current clinical guidelines allow the diagnosis of ALD without genetic confirmation, due to the variety of ALD “masks” and frequent untimely diagnosis of this disease, sequencing of the ABCD1 gene is advisable. In order to correct adrenal insufficiency, the patient was prescribed hormone replacement therapy (HRT) with hydrocortisone, which eliminated the main clinical manifestations and partially laboratory signs of hypocorticism. However, corticotropin levels indicated inadequacy of HRT and increased risk of secondary corticotropinoma growth. However, the patient has been receiving intrathecal therapy with the GABA agonist baclofen for the past five years. The literature has not yet described the response of stress hormones to intrathecal administration of baclofen in patients with primary hypocorticism. The few data available indicate that GABA agonists may have a multidirectional effect on hypothalamic-pituitary function; therefore, it is difficult to determine the contribution of this effect on corticotropin secretion in this patient.
- Open Access
- 18 January 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 23,p. 50-59
Cardioprotection with levocarnitine intracoronary administration during percutaneous coronary interventions
Currently, the number of percutaneous coronary interventions (PCI) performed in acute and chronic forms of coronary heart disease continues to grow: every year their number reaches at least 5,000,000 worldwide, and more than 200,000 of them in Russia. The main causes of postoperative mortality are perioperative myocardial infarction and acute heart failure due to inadequate protection of the myocardium from ischemia/reperfusion under conditions of balloon expansion and stenting of the affected coronary arteries. The review presents experimental and clinical literature data on the successful use of levocarnitine for cardioprotection in patients with various forms of coronary heart disease and patients with chronic heart failure, both with intravenous administration and as part of a cardioplegic solution during heart surgery. The intracoronary route of administration of levocarnitine solution during PCI in high-risk patients (elderly and senile patients, with multivessel lesions of the coronary bed, difficulties in conducting the intervention) is substantiated. The description of two clinical cases of the use of the technique in elderly patients with acute forms of coronary heart disease with multivessel lesion is given. The postoperative period proceeded without complications with smooth dynamics of biomarkers (troponin I, total creatinephosphokinase, MB-fraction of creatinephosphokinase, lactate dehydrogenase), ischemic ECG shifts were little pronounced. The expected results of the application of the technique are a reduction in intraoperative and postoperative complications of ischemia/ reperfusion and an increase in the effectiveness of the clinical results of PCI in high-risk patients.
- 18 January 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 23,p. 50-59
Open AccessCardioprotection with levocarnitine intracoronary administration during percutaneous coronary interventions
Currently, the number of percutaneous coronary interventions (PCI) performed in acute and chronic forms of coronary heart disease continues to grow: every year their number reaches at least 5,000,000 worldwide, and more than 200,000 of them in Russia. The main causes of postoperative mortality are perioperative myocardial infarction and acute heart failure due to inadequate protection of the myocardium from ischemia/reperfusion under conditions of balloon expansion and stenting of the affected coronary arteries. The review presents experimental and clinical literature data on the successful use of levocarnitine for cardioprotection in patients with various forms of coronary heart disease and patients with chronic heart failure, both with intravenous administration and as part of a cardioplegic solution during heart surgery. The intracoronary route of administration of levocarnitine solution during PCI in high-risk patients (elderly and senile patients, with multivessel lesions of the coronary bed, difficulties in conducting the intervention) is substantiated. The description of two clinical cases of the use of the technique in elderly patients with acute forms of coronary heart disease with multivessel lesion is given. The postoperative period proceeded without complications with smooth dynamics of biomarkers (troponin I, total creatinephosphokinase, MB-fraction of creatinephosphokinase, lactate dehydrogenase), ischemic ECG shifts were little pronounced. The expected results of the application of the technique are a reduction in intraoperative and postoperative complications of ischemia/ reperfusion and an increase in the effectiveness of the clinical results of PCI in high-risk patients.
- 2 December 2023
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 27 (4) , 34-42
Urological disorders in adrenoleukodystrophy / adrenomyeloneuropathy
Adrenoleukodystrophy (ALD) is the most common peroxisomal disease of X-linked recessive inheritance caused by a mutation in the ABCD 1 gene located on chromosome Xq28. A characteristic feature of ALD is the lack of correlation between genotype and phenotype. Depending on the time of onset, the main manifestations, and the rate of symptom progression, there are 6 main forms of the disease, but the most common is adrenomyeloneuropathy (AMN). When carefully examining patients with AMI, in most cases it is possible to identify urological pathology manifested by overactive bladder in both sexes and hypogonadism in men, which are hidden behind other numerous neurological symptoms and often remain undiagnosed. To date, there are few works devoted to the peculiarities of pathogenesis, clinical course, diagnosis and treatment of this pathology in ALD. In this article, we reviewed the current literature data on neurogenic bladder dysfunction and hypogonadism in ALD.
- 2 December 2023
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 27 (4) , 34-42
Urological disorders in adrenoleukodystrophy / adrenomyeloneuropathy
Adrenoleukodystrophy (ALD) is the most common peroxisomal disease of X-linked recessive inheritance caused by a mutation in the ABCD 1 gene located on chromosome Xq28. A characteristic feature of ALD is the lack of correlation between genotype and phenotype. Depending on the time of onset, the main manifestations, and the rate of symptom progression, there are 6 main forms of the disease, but the most common is adrenomyeloneuropathy (AMN). When carefully examining patients with AMI, in most cases it is possible to identify urological pathology manifested by overactive bladder in both sexes and hypogonadism in men, which are hidden behind other numerous neurological symptoms and often remain undiagnosed. To date, there are few works devoted to the peculiarities of pathogenesis, clinical course, diagnosis and treatment of this pathology in ALD. In this article, we reviewed the current literature data on neurogenic bladder dysfunction and hypogonadism in ALD.
- Open Access
- 21 October 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 117-127
Hemopericardium after coronary artery stenting: clinical observations and literature review
Currently, at least 5,000,000 patients with coronary artery disease undergo percutaneous coronary interventions with stent implantation every year in the world, and more than 200,000 in Russia. Dissection and perforation of the coronary artery are quite rare, but they are very dangerous complications leading to the development of hemopericardium with cardiac tamponade, cardiogenic shock, myocardial infarction, various arrhythmias and death. The frequency of cardiac tamponade in interventional cardiology, according to various authors, ranges from 0.1 to 3.0% of all interventions. The frequency of deaths cited in the literature also varies greatly (0–20–40%). At the same time, there are no special registers that accumulate data on coronary artery perforations in concrete countries and in the world as a whole. Unfortunately, today, there is still no clear algorithm for identifying high-risk patients, the necessary timing of their intensive follow-up is not clear, and the criteria for choosing between conservative, angiosurgical and operative treatment tactics are not defined. In addition to a literary review of recent sources on this topic, the article presents 3 clinical cases of hemopericardium development in elderly patients at different times after percutaneous interventions, with different symptoms and with different outcomes. The observations illustrate the variability of symptoms, the complexity of diagnosis and treatment, and also touch upon the issues of a multidisciplinary approach with the participation of specialists of different profiles (X-ray angiosurgeons, cardiac surgeons, intensive care specialists, cardiologists and doctors of functional diagnostics).
- 21 October 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 117-127
Open AccessHemopericardium after coronary artery stenting: clinical observations and literature review
Currently, at least 5,000,000 patients with coronary artery disease undergo percutaneous coronary interventions with stent implantation every year in the world, and more than 200,000 in Russia. Dissection and perforation of the coronary artery are quite rare, but they are very dangerous complications leading to the development of hemopericardium with cardiac tamponade, cardiogenic shock, myocardial infarction, various arrhythmias and death. The frequency of cardiac tamponade in interventional cardiology, according to various authors, ranges from 0.1 to 3.0% of all interventions. The frequency of deaths cited in the literature also varies greatly (0–20–40%). At the same time, there are no special registers that accumulate data on coronary artery perforations in concrete countries and in the world as a whole. Unfortunately, today, there is still no clear algorithm for identifying high-risk patients, the necessary timing of their intensive follow-up is not clear, and the criteria for choosing between conservative, angiosurgical and operative treatment tactics are not defined. In addition to a literary review of recent sources on this topic, the article presents 3 clinical cases of hemopericardium development in elderly patients at different times after percutaneous interventions, with different symptoms and with different outcomes. The observations illustrate the variability of symptoms, the complexity of diagnosis and treatment, and also touch upon the issues of a multidisciplinary approach with the participation of specialists of different profiles (X-ray angiosurgeons, cardiac surgeons, intensive care specialists, cardiologists and doctors of functional diagnostics).
- Open Access
- 3 May 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 6,p. 28-34
Experience in the treatment of patients with pulmonary embolism using apixaban and ultrasound inhalations of unfractionated heparin
Introduction. Pulmonary embolism (PE) is one of the leading causes of death even in hospitalized patients. The standard treatment results are disappointing. Since 2004, we have tested a new method for the treatment of hemodynamically insignificant PE (own patent RU2224525C1) by using unfractionated heparin (UFH) in ultrasound inhalations with a nebulizer, since 2014 – in combination with apixaban. Aim. To improve the treatment of PE. Materials and methods. The hospital mortality rate of 713 patients of the cardiac intensive care unit with hemodynamically insignificant PE (from January 1, 2002 to December 31, 2017) was studied. Since 2004, patients have received ultrasound UFH (5000 units twice a day). Since 2014, nebulased UFH has been supplemented with the use of apixaban (10 mg twice a day for 7 days and 5 mg twice a day thereafter). Results and discussion. There is a distinct tendency to the PE hospital mortality decrease, coinciding with the nebulased UFH use (illustrated by a diagram). Neither the systemic bleeding nor the heparin-induced thrombocytopenia were observed. Clinical cases show first reduction of perfusion disorders are seeing scintigraphicaly in 7 days. Unlike LMWH UFH is recommended in severe kidney damage and obesity, thus ultrasound technique has advantages in such patients. Conclusions. Nebulased UFH is an available, simple, safe and effective in treatmtnt of hemodynamically insignificant PE, especially with the use of apixaban. A real improvement in lung perfusion takes 1 week, as shown scintigraphically.
- 3 May 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 6,p. 28-34
Open AccessExperience in the treatment of patients with pulmonary embolism using apixaban and ultrasound inhalations of unfractionated heparin
Introduction. Pulmonary embolism (PE) is one of the leading causes of death even in hospitalized patients. The standard treatment results are disappointing. Since 2004, we have tested a new method for the treatment of hemodynamically insignificant PE (own patent RU2224525C1) by using unfractionated heparin (UFH) in ultrasound inhalations with a nebulizer, since 2014 – in combination with apixaban. Aim. To improve the treatment of PE. Materials and methods. The hospital mortality rate of 713 patients of the cardiac intensive care unit with hemodynamically insignificant PE (from January 1, 2002 to December 31, 2017) was studied. Since 2004, patients have received ultrasound UFH (5000 units twice a day). Since 2014, nebulased UFH has been supplemented with the use of apixaban (10 mg twice a day for 7 days and 5 mg twice a day thereafter). Results and discussion. There is a distinct tendency to the PE hospital mortality decrease, coinciding with the nebulased UFH use (illustrated by a diagram). Neither the systemic bleeding nor the heparin-induced thrombocytopenia were observed. Clinical cases show first reduction of perfusion disorders are seeing scintigraphicaly in 7 days. Unlike LMWH UFH is recommended in severe kidney damage and obesity, thus ultrasound technique has advantages in such patients. Conclusions. Nebulased UFH is an available, simple, safe and effective in treatmtnt of hemodynamically insignificant PE, especially with the use of apixaban. A real improvement in lung perfusion takes 1 week, as shown scintigraphically.